出品|达摩财经4月24日,微信公众号“梅斯肿瘤新前沿”发表致歉声明称,此前由于平台对合作方投放内容审核疏漏,引发争议性内容传播事件。平台已经对此事件进行处理与整改,同时向社会各界致歉。事件的起因要追溯至4月21日。当日,“梅斯肿瘤新前沿”推送了 8 篇文章,文章推送后马上引发了医药界竞相关注,8篇文章的标题首字连起来为“佰泽安无生存获益”。无生存获益是指在临床试验中,某种治疗方法或药物在延长...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.